top of page
Engineering Molecules. Redefining Cancer Care.
Empowering patients with innovative prostate cancer treatments is our mission. ARMA Bio leverages unique technology to tackle the most pressing challenges in cancer therapeutics addressing treatment resistance.
Driven by Innovation
ARMA Bio is an early-stage biotech startup dedicated to developing advanced therapeutics for prostate cancer, leveraging insights from groundbreaking research conducted at Weill Cornell Medicine.
Our Approach
Our core development focuses on the Androgen Receptor (AR) and its variant AR-V7. ARMA Bio has developed first-in-class small-molecule “glue degrader” targeting AR-V7 and AR, simultaneously addressing the key driver of prostate cancer and its resistance-conferring variant, in a single treatment.
Unique Mechanism of Action
ARMA Bio’s compounds bind to a unique domain shared by both AR and AR-V7, a domain that has not been targeted by any other therapeutic modality. This approach enables us to treat all patients with prostate cancer, including those with early-stage, advanced-stage, treatment-sensitive, or treatment-resistant disease.
Preclinical studies demonstrate that our compounds:
-
Effectively inhibit prostate cancer growth at nanomolar concentrations.
-
Are selective for AR/AR-V7 over other nuclear hormone receptors.
-
Rapidly eliminate their targets within hours of treatment.
-
Reverse standard-of-care treatment resistance, addressing a critical unmet clinical need for patients with advanced disease.
Our Team
Co-Founder and Scientific Advisor
Paraskevi Giannakakou, Ph.D
Professor of Pharmacology in Medicine
Weill Cornell Medical College
Co-Founder and Head of Research
Cheuk Man Cherie Au, Ph.D
Assistant Professor in Medicine
Weill Cornell Medical College
Co-Founder and Chemistry Consultant
K.C Nicolaou, Ph.D
Wiess Professor of Chemistry
Rice University
bottom of page